Orthocell (OCC) AGM 2026 presentation summary

Opening remarks and agenda

• Chair John Van Der Wielen acknowledged shareholder disappointment with the share-price response despite progress, and reiterated a focus on execution, growth and long-term value.

• FY2026 marked a continued shift from development-stage biotech toward commercial execution and growth.

Financial performance review

• FY2026 revenue grew 45% YoY; funds available were A$39.0M at 30 September 2026, with no long-term secured debt.

• Q1 FY2027 operating cash use was A$4.5M and normalised cash use A$3.9M; no additional funding was anticipated to support Remplir commercialisation and reach profitability.

• October 2026 U.S. Remplir sales were 92 units and A$279,000, 84% above the Q1 FY2027 monthly average of 50 units.

Board and executive committee updates

• Chair John Van Der Wielen said the strategy, commercial platform and balance sheet positioned the business for its next growth phase; he thanked CEO Paul Anderson, directors, staff, clinicians, partners, distributors and shareholders.